These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 8982661)

  • 21. Novel benzodioxopiperazines acting as antagonists at postsynaptic 5-HT1A receptors and as agonists at 5-HT1A autoreceptors: a comparative pharmacological characterization with proposed 5-HT1A antagonists.
    Millan MJ; Canton H; Gobert A; Lejeune F; Rivet JM; Bervoets K; Brocco M; Widdowson P; Mennini T; Audinot V
    J Pharmacol Exp Ther; 1994 Jan; 268(1):337-52. PubMed ID: 8301575
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Agonist properties of pindolol at h5-HT1A receptors coupled to mitogen-activated protein kinase.
    Millan MJ; Newman-Tancredi A; Duqueyroix D; Cussac D
    Eur J Pharmacol; 2001 Jul; 424(1):13-7. PubMed ID: 11470255
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Beta-adrenoceptor blockade in rats enhances the ambulation induced by 5-HT1A receptor agonists.
    Kalkman HO
    Eur J Pharmacol; 1989 Dec; 173(2-3):121-5. PubMed ID: 2576226
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Differentiation of 5-HT1A receptor ligands by drug discrimination.
    Wolff MC; Leander JD
    Eur J Pharmacol; 1997 Aug; 333(2-3):113-22. PubMed ID: 9314023
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacological characterization of in vivo properties of putative mixed 5-HT1A agonist/5-HT(2A/2C) antagonist anxiolytics. II. Drug discrimination and behavioral observation studies in rats.
    Kleven MS; Assié MB; Koek W
    J Pharmacol Exp Ther; 1997 Aug; 282(2):747-59. PubMed ID: 9262338
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Determination of the 5-HT receptor subtype involved in 8-OH-DPAT-induced hyperlocomotion: potential difficulties arising from inadequate pharmacological tools.
    Kalkman HO; Soar J
    Eur J Pharmacol; 1990 Dec; 191(3):383-90. PubMed ID: 2150821
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Characterization of the aminomethylchroman derivative BAY x 3702 as a highly potent 5-hydroxytryptamine1A receptor agonist.
    De Vry J; Schohe-Loop R; Heine HG; Greuel JM; Mauler F; Schmidt B; Sommermeyer H; Glaser T
    J Pharmacol Exp Ther; 1998 Mar; 284(3):1082-94. PubMed ID: 9495870
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Antagonist properties of (-)-pindolol and WAY 100635 at somatodendritic and postsynaptic 5-HT1A receptors in the rat brain.
    Corradetti R; Laaris N; Hanoun N; Laporte AM; Le Poul E; Hamon M; Lanfumey L
    Br J Pharmacol; 1998 Feb; 123(3):449-62. PubMed ID: 9504386
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Mediation of the antidepressant-like effect of 8-OH-DPAT in mice by postsynaptic 5-HT1A receptors.
    Luscombe GP; Martin KF; Hutchins LJ; Gosden J; Heal DJ
    Br J Pharmacol; 1993 Mar; 108(3):669-77. PubMed ID: 8467355
    [TBL] [Abstract][Full Text] [Related]  

  • 30. 4-(2'-Methoxyphenyl)-1-[2'-[N-(2"-pyridinyl)-p-iodobenzamido]ethyl] piperazine and 4-(2'-methoxyphenyl)-1-[2'-[N-(2"-pyridinyl)-p- fluorobenzamido]ethyl]piperazine, two new antagonists at pre- and postsynaptic serotonin-1A receptors.
    Thielen RJ; Fangon NB; Frazer A
    J Pharmacol Exp Ther; 1996 May; 277(2):661-70. PubMed ID: 8627543
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects of novel 5-HT1A receptor antagonists on measures of post-synaptic 5-HT1A receptor activation in vivo.
    Thielen RJ; Frazer A
    Life Sci; 1995; 56(7):PL163-8. PubMed ID: 7869825
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Interaction studies of 5-HT1A receptor antagonists and selective 5-HT reuptake inhibitors in isolated aggressive mice.
    Sànchez C
    Eur J Pharmacol; 1997 Sep; 334(2-3):127-32. PubMed ID: 9369340
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Enhancement and depression of spinal reflexes by 8-hydroxy-2-(di-n-propylamino)tetralin in the decerebrated and spinalized rabbit: involvement of 5-HT1A- and non-5-HT1A-receptors.
    Clarke RW; Ogilvie J; Houghton AK
    Br J Pharmacol; 1997 Oct; 122(4):631-8. PubMed ID: 9375958
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Further investigation of the in vivo pharmacological properties of the putative 5-HT1A antagonist, BMY 7378.
    Sharp T; Backus LI; Hjorth S; Bramwell SR; Grahame-Smith DG
    Eur J Pharmacol; 1990 Feb; 176(3):331-40. PubMed ID: 1970304
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pindolol antagonises G-protein activation at both pre- and postsynaptic serotonin 5-HT1A receptors: a.
    Newman-Tancredi A; Chaput C; Touzard M; Millan MJ
    Naunyn Schmiedebergs Arch Pharmacol; 2001 Apr; 363(4):391-8. PubMed ID: 11330332
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Displacement of the binding of 5-HT(1A) receptor ligands to pre- and postsynaptic receptors by (-)pindolol. A comparative study in rodent, primate and human brain.
    Raurich A; Mengod G; Artigas F; Cortés R
    Synapse; 1999 Oct; 34(1):68-76. PubMed ID: 10459173
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of WAY 100635 and (-)-5-Me-8-OH-DPAT, a novel 5-HT1A receptor antagonist, on 8-OH-DPAT responses.
    Trillat AC; Malagié I; Mathé-Allainmat M; Anmela MC; Jacquot C; Langlois M; Gardier AM
    Eur J Pharmacol; 1998 Apr; 347(1):41-9. PubMed ID: 9650846
    [TBL] [Abstract][Full Text] [Related]  

  • 38. MP-3022, a new putative antagonist at pre- and postsynaptic 5-HT1A receptors.
    Przegaliński E; Filip M; Bijak M; Wedzony K; Budziszewska B; Tokarski K; Maćkowiak M; Fijał K
    Pol J Pharmacol; 1996; 48(1):13-22. PubMed ID: 9112623
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Interactions of lesopitron (E-4424) with central 5-HT1A receptors: in vitro and in vivo studies in the rat.
    Haj-Dahmane S; Jolas T; Laporte AM; Gozlan H; Farré AJ; Hamon M; Lanfumey L
    Eur J Pharmacol; 1994 Apr; 255(1-3):185-96. PubMed ID: 8026543
    [TBL] [Abstract][Full Text] [Related]  

  • 40. S 14671: a naphtylpiperazine 5-hydroxytryptamine1A agonist of exceptional potency and high efficacy possessing antagonist activity at 5-hydroxytryptamine1C/2 receptors.
    Millan MJ; Rivet JM; Canton H; Lejeune F; Bervoets K; Brocco M; Gobert A; Lefebvre de Ladonchamps B; Le Marouille-Girardon S; Verriele L
    J Pharmacol Exp Ther; 1992 Aug; 262(2):451-63. PubMed ID: 1323650
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.